scholarly journals Safety and metabolic effects of tesamorelin, a growth hormone-releasing factor analogue, in patients with type 2 diabetes: A randomized, placebo-controlled trial

PLoS ONE ◽  
2017 ◽  
Vol 12 (6) ◽  
pp. e0179538 ◽  
Author(s):  
David R. Clemmons ◽  
Sam Miller ◽  
Jean-Claude Mamputu
Keyword(s):  
Type 2 Diabetes ◽  
Growth Hormone ◽  
Controlled Trial ◽  
Metabolic Effects ◽  
Growth Hormone Releasing Factor

scholarly journals Blood Pressure and Metabolic Effects of Acetyl-l-Carnitine in Type 2 Diabetes: DIABASI Randomized Controlled Trial

2018 ◽  
Vol 2 (5) ◽  
pp. 420-436 ◽  
Author(s):  
Aneliya Parvanova ◽  
Matias Trillini ◽  
Manuel A Podestà ◽  
Ilian P Iliev ◽  
Carolina Aparicio ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Type 2 Diabetes ◽  
Randomized Controlled Trial ◽  
Controlled Trial ◽  
Metabolic Effects ◽  
Randomized Controlled

scholarly journals Metabolic Effects of a Growth Hormone-Releasing Factor in Obese Subjects with Reduced Growth Hormone Secretion: A Randomized Controlled Trial

2012 ◽  
Vol 97 (12) ◽  
pp. 4769-4779 ◽  
Author(s):  
Hideo Makimura ◽  
Meghan N. Feldpausch ◽  
Alison M. Rope ◽  
Linda C. Hemphill ◽  
Martin Torriani ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Randomized Controlled Trial ◽  
Controlled Trial ◽  
Hormone Secretion ◽  
Growth Hormone Secretion ◽  
Metabolic Effects ◽  
Growth Hormone Releasing Factor ◽  
Randomized Controlled ◽  
Obese Subjects

Metabolic effects ofLactobacillus reuteriDSM 17938 in people with type 2 diabetes: A randomized controlled trial

2017 ◽  
Vol 19 (4) ◽  
pp. 579-589 ◽  
Author(s):  
Reza Mobini ◽  
Valentina Tremaroli ◽  
Marcus Ståhlman ◽  
Fredrik Karlsson ◽  
Max Levin ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Randomized Controlled Trial ◽  
Controlled Trial ◽  
Metabolic Effects ◽  
Randomized Controlled

scholarly journals Effect of a New Formulation of Nutraceuticals as an Add-On to Metformin Monotherapy for Patients with Type 2 Diabetes and Suboptimal Glycemic Control: A Randomized Controlled Trial

Nutrients ◽  
2021 ◽  
Vol 13 (7) ◽  
pp. 2373
Author(s):  
Giovanni Sartore ◽  
Eugenio Ragazzi ◽  
Giulia Antonello ◽  
Chiara Cosma ◽  
Annunziata Lapolla
Keyword(s):  
Type 2 Diabetes ◽  
Controlled Trial ◽  
Fasting Blood Glucose ◽  
Metabolic Effects ◽  
Chromium Picolinate ◽  
Control Group ◽  
Metformin Monotherapy ◽  
Glycation End Products ◽  
New Formulation

The aim of the study was to evaluate the overall biohumoral and metabolic effects of a 12-week add-on therapy consisting of a new nutraceutical formulation (BHC) based on berberine, hesperidin, and chromium picolinate in type 2 diabetes mellitus (T2D) patients with suboptimal glycemic compensation receiving metformin. After 12 weeks, participants in the group receiving metformin plus BHC, compared to the group receiving metformin only, saw a significant improvement in their glucose profile, in terms of both glycated hemoglobin (HbA1c) and fasting blood glucose (FBG). Their FBG dropped from 145 ± 20 mg/dL to 128 ± 23 mg/dL (p < 0.01), a decrease of 11.7% compared with the baseline. This decrease differed significantly from the situation in the control arm (p < 0.05). HbA1c decreased by 7.5% from the baseline, from 53.5 ± 4.3 mmol/mol to 49.5 ± 5.1 mmol/mol (p < 0.01), in the group given BHC, while no difference was seen in the control group. Advanced glycation end products (AGEs) and malondialdehyde (MDA) were found to be significantly reduced (p < 0.01) only in the BHC group, from 9.34 ± 7.61 μg/mL to 6.75 ± 6.13 μg/mL, and from 1.7 ± 0.15 μmol/L to 1.4 ± 0.25 μmol/L, respectively. In patients with T2D taking metformin with suboptimal glycemic compensation, adding BHC for 3 months significantly improved glucose control in terms of FBG and HbA1c, and had a positive effect on the lipid peroxidation profile, as indicated by a decrease in AGEs and MDA.

Abstract #203 The Real Life Effectiveness; Metabolic Effects and Tolerability of Hydroxychloroquine Once Daily in the Treatment of Type-2 Diabetes Mellitus

2018 ◽  
Vol 24 ◽  
pp. 28-29
Author(s):  
Hemant Thacker ◽  
Rupal Shrimanker ◽  
Banshi Saboo ◽  
Diabetologist ◽  
Anuj Maheshwari ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Real Life ◽  
Metabolic Effects ◽  
Life Effectiveness ◽  
Once Daily ◽  
The Real

Intervention of the Flash Glucose Sensing Technology on Glycemic Control and Treatment Satisfaction in Patients with Type 2 Diabetes Treated Intensively by Insulin—A Randomized Controlled Trial

Diabetes ◽  
2018 ◽  
Vol 67 (Supplement 1) ◽  
pp. 908-P ◽  
Author(s):  
MARIANNA YARON ◽  
EYTAN ROITMAN ◽  
GENYA AHARON-HANANEL ◽  
ZOHAR LANDAU ◽  
TALI GANZ ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Randomized Controlled Trial ◽  
Glycemic Control ◽  
Treatment Satisfaction ◽  
Controlled Trial ◽  
Glucose Sensing ◽  
Randomized Controlled ◽  
Sensing Technology

1559-P: Differential Effects of Type 1 (T1D) and Type 2 Diabetes (T2D) on the Growth Hormone (GH)-Insulin-Like Growth Factor (IGF) Axis in Youth

Diabetes ◽  
2019 ◽  
Vol 68 (Supplement 1) ◽  
pp. 1559-P
Author(s):  
JANET K. SNELL-BERGEON ◽  
JANE E.B. REUSCH ◽  
AMY D. BAUMGARTNER ◽  
MELANIE CREE-GREEN ◽  
KRISTEN J. NADEAU
Keyword(s):  
Type 2 Diabetes ◽  
Growth Hormone ◽  
Growth Factor ◽  
Insulin Like Growth Factor ◽  
Differential Effects
Sign in / Sign up

Export Citation Format

Share Document